💡LIDOPAN study: multicenter pilot trial 💉 IV lidocaine for patients in pain with PDAC and CP 👥30 patients, NRS >4 📈 No overall clinically relevant pain reduction day 1 🤩 31% positive effect, lasted op to a month https://t.co/uNzbw4WAI9 @ACG_CTG

Very honored to give the @YouppiePancreas award 🏆presentation at #EPC2024: looking beyond trial results in pancreatic research ⭐️ Key points: 1️⃣ Improve international comparison 2️⃣ Use of alternative RCT designs 3️⃣ Importance of implementation @DPCG_official

Heb je het al gehoord? Op 13 april gaan we fietsen in de Drunense Duinen in Noord-Brabant. Een kans om een sportieve fietstocht te combineren met steun voor het Deltaplan Alvleesklierkanker. We rijden ANWB-fietsroutes van 50, 80 en 130 km https://t.co/xV8LtfPGya

Timing of initiation of chemotherapy in asymptomatic metastatic PDAC? 1⃣ Expert opinion: 67% prefer immediate start of chemo 2⃣ Meta-analysis: limited evidence available - no survival difference, potential QOL benefit delayed start of chemo 3⃣ Protocol: let's wait and see! 🙏

New study by @DPCG_official: TIMEPAN trial ⏰ Asymptomatic metastatic PDAC: ▶️Immediate start chemotherapy ⏸️Start when symptoms occur Primary outcome: quality adjusted survival 👩🏼‍⚕️ ➡️Full protocol: https://t.co/kkSWDBLVav

Study protocol #ENDURO multicenter RCT @DPCG_official: EUS- vs surgical gastro-jejunostomy in patients with malignant gastric outlet obstruction. @FrankVleggaar ➡️Inclusion is on schedule https://t.co/Xn0O3l3VO7 #PancreaticCancer #alvleesklierkanker

Congrats #DeesjeDoppenberg on a wonderful #PhD on SBRT radiotherapy and surgery in localized #PancreaticCancer Interested? #Thesis ➡️ https://t.co/PT1qIgEjCX 7 studies, 75 co-authors incl #PANCOSAR RCT and #ULTRAPANC study. Thanks to @AnnA25_03 @DPCG_official and #TAPS

Should #neoadjuvant #chemorad only be offered in #PancreaticCancer pts with high CA19.9? Probably not! Joint analysis #PREOPANC 🇳🇱 and #Jang 🇰🇷 multicenter trials: ✅ 127pts low CA19-9 <500: mOS 23.5 vs 16.3 mo (HR 0.63, 0.42 to 0.93) ❌ 52pts high CA19-9 >500: mOS 15.5 vs

@pancreatitis_nl @DPCG_official never ceases to amaze us 🥰👏👍 @MarcBesselink discussing ongoing and still needed studies in Pancreatology 😇 @jayanta_sam @DeMadaria @lelecapurso @AntonioFaccior6 @CrinoStefano @docdhir @JoanB_Gornals @GIPapachristou @ClubPancreas @verdonk

@EurPancClub #EPC2023 @BorisJanssen on behalf of @PHAIRconsortium! AI residual cancer burden (RCB) to evaluate impact of NAT in resected pancreatic cancer! RCB 🔬 NAT vs. upfront: 2.2 vs. 10.3 mm2 p<0.0001 Survival 📈 Above vs. below median RCB: 24 vs. 30 months. p=0.018

Amazing 30+ year old tradition celebrating #Surgical #TeamSpirit: yesterday, #Chirurgencup 🇳🇱(#SurgeonsCup) day between all 7 training regions for #GeneralSurgery 700+ #surgeons, #residents, #PhDstudents incl 2 @amsterdamumc region teams playing ⚽️🏑🏐🤽‍♂️🎾♣️ and more incl a live

What are the learning curves for 🤖 #Robotic #Pancreatoduodenectomy in trained “2nd generation” centers? 635 RPDs performed by teams of 17 surgeons in 7 🇳🇱 @DPCG_official centers. All trained in LAELAPS-3 by @HoggNDMD @herbert_zeh @AmerZureikatMD Conversion rate 6.6%,

🚴🏻‍♀️ Help support the @CycLyon2023 team! 🇫🇷 Cycling 650 km from Brescia to @EAHPBA Lyon 🎶 Please add a song to the support playlist: https://t.co/7OBmfdJr5F

📢 Exciting news! The @PHAIRconsortium is officially launching today! 🎉 Launch + excellent presentations by: @LoisDaamen, @gimalleo, @AAFretland, @ammar_asrar, and Jackie Bereska. PHAIR aims to drive AI advancements for patients with pancreaticobiliary and hepatic diseases.

#IntraoperativeUltrasound During #SurgicalExploration in Patients with #PancreaticCancer and Vascular Involvement ( #ULTRAPANC ): A Prospective Multicenter Study https://t.co/xO4mzHO4xH #VisualAbstract

CycLyon 2023: from June 1st to June 6th, a dedicated team of medical researchers will cycle from Brescia to Lyon, to raise funds for pancreatic cancer research. We invite you to follow our journey and support us on Instagram, Facebook, Twitter, and LinkedIn! 🚴‍♂️

📜by the 🇳🇱 Panc Study group: Network treatment (centralized surgery in expert🏥, adjuvant chemo in local🏥) after panc🔪did not influence time to/completition chemo nor survival! https://t.co/eIAaazhhDE @DPCG_official @pancreatitis_nl @PancreasClub #some4hpb #SoMe4Surgery

Harmonizing the USA 🇺🇸 and European🇪🇺 composite markers of #Pancreas #Surgery into one 🌎 global “#Ideal #Outcome”: allows comparison of surgical outcomes @Simone_Aug presenting a #GAPASURG project combining data from the registries from: 🇺🇸 🇳🇱 🇩🇪 🇸🇪 https://t.co/vIc7SapChk

🧡Team🇳🇱 @DPCG_official and @pancreatitis_nl at @PancreasClub #PancreasClub2023 #Chicago presenting our nationwide collaborative research in #PancreaticCancer #Pancreatitis #Surgery Excellent meeting with lenghty discussions…and our slightly hidden supporter: @EAHPBA president

Last call ‼️ Closing 1st May 😱 Are differences in ASA score in HPB surgery actually related to patient factors? Complete MILESTONE-2 survey: https://t.co/5VZfo9qzAr Already > 1200 responses, from over 53 countries! 🌍